ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $74,725 | +38.4% | 798 | +31.9% | 0.00% | +100.0% |
| Q2 2023 | $53,996 | -60.6% | 605 | -52.6% | 0.00% | -75.0% |
| Q1 2023 | $136,920 | -16.4% | 1,277 | -4.8% | 0.00% | -20.0% |
| Q4 2022 | $163,776 | +23.1% | 1,341 | +3.8% | 0.01% | 0.0% |
| Q3 2022 | $133,000 | +79.7% | 1,292 | +63.1% | 0.01% | +66.7% |
| Q2 2022 | $74,000 | +138.7% | 792 | +201.1% | 0.00% | +200.0% |
| Q1 2022 | $31,000 | -64.8% | 263 | -59.9% | 0.00% | -66.7% |
| Q4 2021 | $88,000 | -16.2% | 656 | -0.3% | 0.00% | -25.0% |
| Q3 2021 | $105,000 | +66.7% | 658 | +36.5% | 0.00% | +33.3% |
| Q2 2021 | $63,000 | +37.0% | 482 | +35.0% | 0.00% | +50.0% |
| Q1 2021 | $46,000 | -2.1% | 357 | +26.1% | 0.00% | 0.0% |
| Q4 2020 | $47,000 | +38.2% | 283 | +27.5% | 0.00% | 0.0% |
| Q3 2020 | $34,000 | +209.1% | 222 | +196.0% | 0.00% | +100.0% |
| Q2 2020 | $11,000 | +175.0% | 75 | +134.4% | 0.00% | – |
| Q1 2020 | $4,000 | – | 32 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |